AzurRx BioPharma (NASDAQ:AZRX) Raised to “Buy” at ValuEngine

ValuEngine upgraded shares of AzurRx BioPharma (NASDAQ:AZRX) from a hold rating to a buy rating in a research note issued to investors on Thursday, ValuEngine reports.

Other analysts have also issued research reports about the company. Maxim Group reissued a buy rating and issued a $5.00 target price on shares of AzurRx BioPharma in a report on Wednesday, April 24th. HC Wainwright reaffirmed a buy rating on shares of AzurRx BioPharma in a research note on Monday, July 29th. Finally, National Securities began coverage on AzurRx BioPharma in a research note on Tuesday, June 11th. They set a buy rating and a $9.00 price objective on the stock. Seven analysts have rated the stock with a buy rating, The stock currently has a consensus rating of Buy and a consensus price target of $7.58.

AzurRx BioPharma stock traded up $0.01 during trading hours on Thursday, hitting $1.04. The stock had a trading volume of 199,868 shares, compared to its average volume of 387,107. AzurRx BioPharma has a 1-year low of $0.91 and a 1-year high of $3.75. The firm has a fifty day simple moving average of $1.36.

AzurRx BioPharma (NASDAQ:AZRX) last posted its earnings results on Wednesday, May 15th. The company reported ($0.26) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.18) by ($0.08). On average, equities research analysts anticipate that AzurRx BioPharma will post -0.76 earnings per share for the current fiscal year.

A hedge fund recently bought a new stake in AzurRx BioPharma stock. Waldron Private Wealth LLC purchased a new position in AzurRx BioPharma Inc (NASDAQ:AZRX) during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 69,835 shares of the company’s stock, valued at approximately $169,000. Waldron Private Wealth LLC owned about 0.38% of AzurRx BioPharma at the end of the most recent quarter. Institutional investors and hedge funds own 10.58% of the company’s stock.

About AzurRx BioPharma

AzurRx BioPharma, Inc researches and develops non-systemic biologics for the treatment of patients with gastrointestinal disorders. Its product pipeline consists of two therapeutic proteins under development, including MS1819, a yeast derived recombinant lipase, which is in Phase II clinical trial for the treatment of exocrine pancreatic insufficiency associated with chronic pancreatitis and cystic fibrosis; and AZX1101, an enzymatic combination of bacterial origin for the prevention of hospital-acquired infections and antibiotic-associated diarrhea.

Read More: What is a blue-chip stock?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for AzurRx BioPharma (NASDAQ:AZRX)

Receive News & Ratings for AzurRx BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AzurRx BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.